FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

- 1								
	OMB APPROVAL							
	OMB Number: 3235-03							
	Estimated average burden							
	hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Koppel Adam  2. Date of Event Requiring Stateme (Month/Day/Year) 01/25/2018				nent	3. Issuer Name and Ticker or Trading Symbol Solid Biosciences, LLC [ SLDB ]							
(Last) (First) (Middle) C/O BAIN CAPITAL LIFE SCIENCES INVESTORS					Relationship of Reporting Person (Check all applicable)     X Director		son(s) to Issuer		5. If Amendment, Date of Original Filed (Month/Day/Year)			
LLC, 200 CL	ARENDON S	TREET				Officer (give title below)	Other (spe	ecify	Appli	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person		
(Street) BOSTON	MA	02116								Form filed by Reporting P	y More than One erson	
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		ct (D)	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock						1,689,444	I		See Footnotes <sup>(1)(2)</sup>			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
Expiration			2. Date Exerc Expiration Da (Month/Day/\	ate	and 3. Title and Amount of Secu Underlying Derivative Secu			4. Conve	rcise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	n Title	•	Amount or Number of Shares	Deriva Securi	tive	or Indirect (I) (Instr. 5)		

## **Explanation of Responses:**

- 1. Represents shares held directly by BCLS SB Investco, LP ("BCLS").
- 2. The governance, investment strategy and decision-making process with respect to investments held by BCLS is directed by Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel. By virtue of the relationships described in these footnotes, Dr. Koppel may be deemed to share voting and dispositive power with respect to all of the shares of Common Stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

## Remarks:

/s/ Adam Koppel

01/25/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.